Telix Pharmaceuticals (TLX) Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for TLX from our risk checks.
TLX Community Fair Values
Create NarrativeSee what 208 others think this stock is worth. Follow their fair value or set your own to get alerts.
TLX... a Market's Overreaction or a Falling Knife?
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Telix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$12.95 |
| 52 Week High | AU$29.64 |
| 52 Week Low | AU$8.26 |
| Beta | 0.61 |
| 1 Month Change | 28.34% |
| 3 Month Change | 14.00% |
| 1 Year Change | -45.20% |
| 3 Year Change | 73.83% |
| 5 Year Change | 204.71% |
| Change since IPO | 1,581.82% |
Recent News & Updates
Recent updates
TLX... a Market's Overreaction or a Falling Knife?
So just for context to any investors happening upon this narrative... What does Telix actually do?The Market Doesn't Like What It Sees From Telix Pharmaceuticals Limited's (ASX:TLX) Revenues Yet As Shares Tumble 26%
Dec 31
We Think You Can Look Beyond Telix Pharmaceuticals' (ASX:TLX) Lackluster Earnings
Aug 27Telix Pharmaceuticals Limited (ASX:TLX) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
Aug 08Here's Why Telix Pharmaceuticals (ASX:TLX) Can Manage Its Debt Responsibly
May 15Shareholder Returns
| TLX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -5.1% | -2.8% | 0.6% |
| 1Y | -45.2% | -43.0% | 11.5% |
Return vs Industry: TLX underperformed the Australian Biotechs industry which returned -43% over the past year.
Return vs Market: TLX underperformed the Australian Market which returned 11.5% over the past year.
Price Volatility
| TLX volatility | |
|---|---|
| TLX Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in AU Market | 17.9% |
| 10% least volatile stocks in AU Market | 4.3% |
Stable Share Price: TLX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: TLX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,152 | Chris Behrenbruch | telixpharma.com |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
Telix Pharmaceuticals Limited Fundamentals Summary
| TLX fundamental statistics | |
|---|---|
| Market cap | AU$4.39b |
| Earnings (TTM) | -AU$10.35m |
| Revenue (TTM) | AU$1.17b |
Is TLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLX income statement (TTM) | |
|---|---|
| Revenue | US$803.79m |
| Cost of Revenue | US$421.95m |
| Gross Profit | US$381.85m |
| Other Expenses | US$388.97m |
| Earnings | -US$7.12m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 47.51% |
| Net Profit Margin | -0.89% |
| Debt/Equity Ratio | 97.5% |
How did TLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/04 20:39 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Telix Pharmaceuticals Limited is covered by 21 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melissa Benson | Barrenjoey Markets Pty Limited |
| John Hester | Bell Potter |
| Shane Storey | Canaccord Genuity |